NASDAQ:BLUEbluebird bio Stock Price, Forecast & News

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BLUE shares have increased by 4.5% and is now trading at $64.27. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for bluebird bio.

bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for bluebird bio.

bluebird bio Inc (NASDAQ:BLUE) posted its earnings results on Monday, May, 11th. The biotechnology company reported ($3.64) EPS for the quarter, beating the consensus estimate of ($4.05) by $0.41. The biotechnology company earned $21.90 million during the quarter, compared to analysts' expectations of $8 million. bluebird bio had a negative return on equity of 60.05% and a negative net margin of 1,531.04%. The firm's revenue was up 75.2% on a year-over-year basis. During the same period in the previous year, the business posted ($2.99) EPS. View bluebird bio's earnings history.

19 brokerages have issued 12-month price objectives for bluebird bio's shares. Their forecasts range from $70.00 to $160.00. On average, they anticipate bluebird bio's stock price to reach $109.31 in the next year. This suggests a possible upside of 70.1% from the stock's current price. View analysts' price targets for bluebird bio.

News headlines about BLUE stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. bluebird bio earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about bluebird bio.

Some companies that are related to bluebird bio include Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Novavax (NVAX), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF) and Iovance Biotherapeutics (IOVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU) and Medivation (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View institutional ownership trends for bluebird bio.

BLUE stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $64.27.

bluebird bio has a market capitalization of $3.58 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

The official website for bluebird bio is www.bluebirdbio.com.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]